According to Future Market Insights (FMI) analysis in a recent market survey, the global spasticity treatment market was valued at US$ 12.2 Billion in 2022 and is set to reach US$ 28.4 Billion by 2033.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 12.2 Billion |
| Market Value 2023 | US$ 13.1 Billion |
| Market Value 2033 | US$ 28.4 Billion |
| CAGR 2023 to 2033 | 8.1% |
| Share of Top 5 Countries | 54.0% |
| Key Players | Medtronic Plc; Piramal Enterprises Ltd.; AbbVie, Inc. (Allergan); Ipsen Pharma; F. Hoffmann-La Roche Ltd; GlaxoSmithKline plc; Pfizer Inc.; Elite Pharmaceuticals Inc.; Orient Pharma; Acorda Therapeutics, Inc.; Sun Pharmaceutical Industries Ltd; Novartis AG (Alcon); Teva Pharmaceutical Industries Ltd; Zydus Cadila Healthcare Ltd.; Beximco Pharmaceuticals Ltd; Merz Pharma; Thought Technology Ltd.; UltraCare PRO; Invacare Corporation; ATI Physical Therapy; P.T. Services Rehabilitation, Inc.; Banner Health. |
Spasticity is one of many clinical traits or motor behavior that can appear following injury to the area of the brain or spinal cord that regulates voluntary movements. Upper motor neuron syndrome is the term used to describe these symptoms taken together.
One of the key factors promoting the growth of the spasticity treatment market is the rising prevalence of neuro-musculoskeletal disorders. Spasticity is becoming more common as chronic neuro-musculoskeletal illnesses become more common on a global scale.
The high prevalence of these illnesses worldwide is a result of an increase in slips, accidents, assaults, and other incidents. A diagnosis of spasticity was made in more than 50% to 60% of these cases. The global market thus benefits from the rising prevalence of various chronic disorders due to the close association between the aforementioned chronic conditions and spasticity. This rising incidence will drive market expansion over the forecast period.
Overall, the adoption of spasticity treatment in healthcare facilities, which will boost the market in the coming years.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sales of the global market grew at a CAGR of 5.4% between 2012 and 2022. Spasticity treatment market contributes 29.6% revenue share to the global neurodegenerative disease treatment market value at US$ 41.2 Billion in 2022.
The ageing population is one of the primary factors fueling the market for spasticity treatments.
Age-related changes in the brain, traumas like stroke or traumatic brain damage, addiction, and diseases like multiple sclerosis (MS), stroke, and brain tumours, among others, can all have a substantial impact on brain health, which will increase the prevalence of spasticity and its related indications, which will boost the market for spasticity treatments.
Advanced procurement operations provide businesses and manufacturers with chances to develop and expand their clientele to buyers and suppliers that collaborate to create cutting-edge products that increase sales and profits for all parties. By implementing several techniques into their processes, they adopt an integrated approach to creating new goods and procedures.
Different key strategies such as new product launches, acquisitions, collaborations, and expansion are being used by companies and different manufacturers for the advancement and development of new products and therapies.
Considering this, FMI expects the global market to grow at a CAGR of 8.1% through the forecasted years.
Cognitive knowledge and evaluation of everyday things and issues is one of the most important indicators of a person's mental health and ability to think and act in life-or-death situations.
The brain is a sophisticated organ that has a significant impact on one's overall health and well-being. Brain health can be significantly impacted by ageing-related changes in the brain and traumas like stroke or traumatic brain injury. While certain factors that affect brain health cannot be avoided, there are other lifestyle changes that can be beneficial.
Since they improve brain glucose metabolism and reduce the risk of mental disorders, improved brain and mental fitness is becoming more and more in demand, opening up new treatment options for spasticity.
Increased testing of combination therapies in patients will pave the way for new drug discoveries and treatment options, ultimately leading to the introduction of new products into the market.
Principal Consultant
For the spasticity treatment process, there is a requirement of skilled specialists such as physiatrists, neurologists, rehabilitation nurses, physical and occupational therapists, speech and language pathologists, psychologists, social workers, recreational therapists, etc.
The non-availability and limited number of such well-trained specialists can have an adverse impact on the treatment of patients with spasticity and also lower the growth of the organizations that are involved in the treatment. Due to these factors, the quality of services can get affected, and this will ultimately have a negative impact on the growth of the spasticity treatment market.
The dearth of skilled professionals in these fields can lower the quality of services offered, ultimately affecting the growth of the spasticity treatment market.
These factors are expected to hamper revenue growth of the global market over the forecast period.
The USA market dominated the global market with value of around US$ 3.63 Bilion in 2022 and is expected to register a CAGR of 8.3% during the forecast period.
The high prevalence of spasticity in the United States will accelerate the acceptance of various treatment alternatives.
Due to the high prevalence, more treatments, including over-the-counter products, will experience a high adoption rate among patients. The demand for spasticity treatment will increase due to high prevalence, which will drive the expansion of the market.
Germany dominated the European market for spasticity treatment and accounted for around 22.3% of the regional market share in 2022.
Increasing technological advancements in spasticity treatment therapies in Germany is driving the overall Europe spasticity treatment market.
Virtual reality technology can be used to provide immersive therapy experiences for patients with spasticity. These experiences can help patients to improve their motor skills and reduce spasticity through interactive and engaging activities. This therapy has been found to be effective in reducing spasticity in patients with cerebral palsy, multiple sclerosis, and other neurological conditions.
The safe and successful spasticity treatment therapies in Germany will influence other European countries to also opt for this treatment method, ultimately expanding the overall market.
China is projected to be the most attractive market in the East Asia region, and is expected to grow over a significant CAGR of 7.7% during the forecast duration.
The spasticity treatment market in China is expected to grow significantly in the coming years due to several factors.
One of the main factors driving the growth of the spasticity treatment market in China is the increasing awareness of the condition among the general public and healthcare professionals. As more people become aware of the condition, they are more likely to seek treatment, which is leading to increased demand for treatments for spasticity.
Another factor contributing to the growth of the spasticity treatment market in China is the increasing availability of advanced medical technologies and treatments. China has made significant investments in its healthcare infrastructure, and many new hospitals and clinics have been built in recent years. This has allowed for the introduction of advanced treatments such as botox injections and surgery, which were not widely available in the past.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The treatment segment utilizing drugs, physical therapy, Botulinum toxin, surgical treatment and others treatment options held the major chunk of about 68.4% in global market by the end of 2022.
With advances in medical technology, it has become easier to diagnose spasticity accurately. This has led to more people being diagnosed with the condition, which in turn has increased the demand for treatment. There is now more awareness about spasticity among healthcare providers, patients, and the general public. This has helped to reduce the stigma associated with the condition and encouraged more people to seek treatment.
There have been significant advances in the development of new treatments for spasticity, including medications, physical therapy, and surgical procedures. These treatments can help to reduce spasticity and improve overall quality of life for people with the condition.
The Cerebral Palsy segment held the major chunk of about 14.4% in global market by the end of 2022.
Increased awareness of cerebral palsy and improved diagnostic techniques have led to more accurate diagnosis and reporting of cases, contributing to the observed increase in prevalence. Certain risk factors, such as maternal infections during pregnancy, prematurity, and low birth weight, have become more common in recent years. This has contributed to the increase in the incidence of cerebral palsy and spasticity.
The hospital pharmacies segment accounted for revenue share of 38.3% in the global market at the end of 2022.
Hospital pharmacies offer convenient access to treatment options, with many providing over-the-counter and prescription medications for a range of conditions, including cerebral palsy, multiple sclerosis among others. Patients can typically purchase these treatments without an appointment, making it more convenient for them to manage their condition.
Overall, hospital pharmacies offers a convenient and accessible distribution channel for spasticity treating products, making it the largest channel for these treatments.
The hospitals segment accounted for revenue share of 37.1% in the global market at the end of 2022.
Hospitals typically have access to a wide range of specialized medical professionals, including neurologists, physiatrists, orthopedic surgeons, and physical therapists, who can collaborate to provide comprehensive spasticity treatment.
Overall, hospitals are a leading segment for spasticity treatment because they provide access to specialized medical professionals, advanced diagnostic tools, multimodal treatments, specialized equipment and facilities, and both inpatient and outpatient services.
Key players in the market are focused on increase their product portfolio to strengthen their position in the spasticity treatment market, and also to expand their footprint in emerging markets. The key strategy adopted by manufacturers to gain competitive edge in the market are the pricing strategies, market strategies, technological advancements, regulatory compliance and acquisition of other companies to expand their business.
For instance:
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the spasticity treatment market space, which are available in the full report
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2012 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, United Kingdom, France, Italy, Spain, Russia, BENELUX, Nordics, India, Thailand, Indonesia, Malaysia, Philippines, Vietnam, China, Japan, South Korea, Australia, New Zealand, Türkiye, South Africa, North Africa and GCC Countries |
| Key Segments Covered | Diagnosis & Treatment Type, Indication, Distribution Channel, Service Providers, and Region |
| Key Companies Profiled | Medtronic Plc; Piramal Enterprises Ltd.; AbbVie, Inc. (Allergan); Ipsen Pharma; F. Hoffmann-La Roche Ltd; GlaxoSmithKline plc; Pfizer Inc.; Elite Pharmaceuticals Inc.; Orient Pharma; Acorda Therapeutics, Inc.; Sun Pharmaceutical Industries Ltd; Novartis AG (Alcon); Teva Pharmaceutical Industries Ltd; Zydus Cadila Healthcare Ltd.; Beximco Pharmaceuticals Ltd; Merz Pharma; Thought Technology Ltd.; UltraCare PRO; Invacare Corporation; ATI Physical Therapy; P.T. Services Rehabilitation, Inc.; Banner Health |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The global market is valued around US$ 12.2 Billion in 2022.
The global market estimates for 2023 is around US$ 13.1 Billion.
The global market is set to reach US$ 28.4 Billion by the end of 2033, with sales revenue expected to be 8.1% CAGR through 2033.
North America dominated the global market in 2022 with the USA being the leading contributor in the North American region.
Rising demand for improved brain and mental fitness and improving healthcare infrastructure to offer lucrative growth opportunities for the market players to grow.
Cerebral palsy segment dominated the global market in 2022 with 14.4% revenue share and is expected to lead in 2023 as well.
The USA, India, China, Germany and United Kingdom are the top countries that are driving the demand for the spasticity treatment globally.
From 2012 to 2022, the market for spasticity treatment expanded at the rate of 5.4%.
Allergan plc. (AbbVie), F. Hoffmann-La Roche Ltd, Pfizer Inc., Medtronic Plc, GlaxoSmithKline plc, are few key players within the global market.
China is projected to grow with CAGR of 7.7% over the forecast duration.
1. Global Market- Executive Summary | Spasticity Treatment Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusion and Exclusion
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Indication Innovation / Development Trends
4. Value Added Insights
4.1. Product Adoption/Usage Analysis, By Region
4.2. Regulatory Scenario
4.3. Data on Insurance Coverage
4.4. Cost of treatment by Key Countries
4.5. Annual Patient Volume of Indications for Key Countries
4.5.1. Cerebral Palsy
4.5.2. Multiple Sclerosis
4.5.3. Amyotrophic Lateral Sclerosis
4.5.4. Hereditary Spastic Paraplegias
4.5.5. Periventricular Leukomalacia
4.5.6. Metabolic Diseases
4.5.7. Traumatic Brain Injury
4.5.8. Spinal Cord Injury
4.5.9. Stroke
4.5.10. Multiple System Atrophy
4.5.11. Stiff-Person Syndrome
4.5.12. Infectious Transvers Myelitis
4.5.13. Encephalopathy
4.5.14. Brain Tumor
4.5.15. Krabbe Disease
4.5.16. Multiple System Atrophy
4.5.17. Johns Hopkins Disease
4.6. Distribution Channel Information
4.7. PESTLE Analysis
4.8. Key Promotional Strategies by Manufacturers
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure Market Outlook
5.1.3. Global Pharmaceutical Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Strategic Developments by Key Players
5.2.2. Technological Advancements
5.2.3. Top Companies Historical Growth
5.2.4. Research and Development Activities
5.2.5. Adoption of in Healthcare Facilities
5.2.6. Cost of Products
5.2.7. Increasing Prevalence of Spasticity Related Indications
5.2.8. GDP Growth
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. Revenue By Indication
6.1.2. Revenue By Diagnosis & Treatment Type
6.1.3. Revenue By Distribution Channel
6.1.4. Revenue By Service Providers
6.1.5. Revenue By Country
6.2. 2022 Market Scenario
7. Global Market Demand (in Value US$ Million) Analysis 2012 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2022
7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, by Diagnosis & Treatment Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis by Diagnosis & Treatment Type, 2012 to 2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Diagnosis & Treatment Type, 2023 to 2033
8.3.1. Diagnosis
8.3.1.1. Inpatient
8.3.1.2. Outpatient
8.3.2. Treatment Type
8.3.2.1. Drug
8.3.2.1.1. Baclofen
8.3.2.1.2. Tizanidine
8.3.2.1.3. Dantrolene sodium
8.3.2.1.4. Diazepam
8.3.2.1.5. Clonazepam
8.3.2.1.6. Gabapentin
8.3.2.1.7. Others
8.3.2.2. Physical Therapy
8.3.2.3. Botulinum injection
8.3.2.4. Surgery Treatment
8.3.2.5. Other Treatment
8.3.3. Devices
8.3.3.1. Reciprocal EMG-Triggered Stimulation
8.3.3.2. Transcutaneous Electrical Nerve Stimulation
8.3.3.3. Bracing and Cuff
8.3.3.4. Leg lifter
8.3.3.5. Cane and Crunches
8.3.3.6. Wheelchair
8.3.3.7. Others
8.4. Market Attractiveness Analysis by Diagnosis & Treatment Type
9. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, by Indication
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis by Indication, 2012 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
9.3.1. Cerebral Palsy
9.3.2. Multiple Sclerosis
9.3.3. Amyotrophic Lateral Sclerosis
9.3.4. Hereditary Spastic Paraplegias
9.3.5. Periventricular Leukomalacia
9.3.6. Metabolic Diseases
9.3.7. Traumatic Brain Injury
9.3.8. Spinal Cord Injury
9.3.9. Stroke
9.3.10. Multiple System Atrophy
9.3.11. Stiff-Person Syndrome
9.3.12. Infectious Transvers Myelitis
9.3.13. Encephalopathy
9.3.14. Brain Tumor
9.3.15. Krabbe Disease
9.3.16. Multiple System Atrophy
9.3.17. Johns Hopkins Disease
9.4. Market Attractiveness Analysis by Indication
10. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Distribution Channel
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2012 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Drug Stores
10.3.4. Online Pharmacies
10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Service Providers
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis By Service Providers, 2012 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Service Providers, 2023 to 2033
11.3.1. Hospitals
11.3.2. Ambulatory Surgical Centers
11.3.3. Home Care Settings
11.3.4. Specialty Clinics
11.3.5. Diagnostic Centers
11.4. Market Attractiveness Analysis By Service Providers
12. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Million) Analysis by Region, 2012 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. South Asia
12.3.5. East Asia
12.3.6. Oceania
12.3.7. Middle East & Africa(MEA)
12.4. Market Attractiveness Analysis by Region
13. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. USA
13.3.1.2. Canada
13.3.2. By Indication
13.3.3. By Diagnosis & Treatment Type
13.3.4. By Distribution Channel
13.3.5. By Service Providers
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Indication
13.4.3. By Diagnosis & Treatment Type
13.4.4. By Distribution Channel
13.4.5. By Service Providers
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis
13.7. Country Level Analysis & Forecast
13.7.1. USA Market
13.7.1.1. Introduction
13.7.1.2. Market Analysis and Forecast by Market Taxonomy
13.7.1.2.1. By Indication
13.7.1.2.2. By Diagnosis & Treatment Type
13.7.1.2.3. By Distribution Channel
13.7.1.2.4. By Service Providers
13.7.2. Canada Market
13.7.2.1. Introduction
13.7.2.2. Market Analysis and Forecast by Market Taxonomy
13.7.2.2.1. By Indication
13.7.2.2.2. By Diagnosis & Treatment Type
13.7.2.2.3. By Distribution Channel
13.7.2.2.4. By Service Providers
14. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast recast by Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Mexico
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Indication
14.3.3. By Diagnosis & Treatment Type
14.3.4. By Distribution Channel
14.3.5. By Service Providers
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Indication
14.4.3. By Diagnosis & Treatment Type
14.4.4. By Distribution Channel
14.4.5. By Service Providers
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
14.7. Country Level Analysis & Forecast
14.7.1. Brazil Market
14.7.1.1. Introduction
14.7.1.2. Market Analysis and Forecast by Market Taxonomy
14.7.1.2.1. By Indication
14.7.1.2.2. By Diagnosis & Treatment Type
14.7.1.2.3. By Distribution Channel
14.7.1.2.4. By Service Providers
14.7.2. Mexico Market
14.7.2.1. Introduction
14.7.2.2. Market Analysis and Forecast by Market Taxonomy
14.7.2.2.1. By Indication
14.7.2.2.2. By Diagnosis & Treatment Type
14.7.2.2.3. By Distribution Channel
14.7.2.2.4. By Service Providers
14.7.3. Argentina Market
14.7.3.1. Introduction
14.7.3.2. Market Analysis and Forecast by Market Taxonomy
14.7.3.2.1. By Indication
14.7.3.2.2. By Diagnosis & Treatment Type
14.7.3.2.3. By Distribution Channel
14.7.3.2.4. By Service Providers
15. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. United Kingdom
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Nordic Countries
15.3.1.8. Russia
15.3.1.9. Rest of Europe
15.3.2. By Indication
15.3.3. By Diagnosis & Treatment Type
15.3.4. By Distribution Channel
15.3.5. By Service Providers
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Indication
15.4.3. By Diagnosis & Treatment Type
15.4.4. By Distribution Channel
15.4.5. By Service Providers
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
15.7. Country Level Analysis & Forecast
15.7.1. Germany Market
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast by Market Taxonomy
15.7.1.2.1. By Indication
15.7.1.2.2. By Diagnosis & Treatment Type
15.7.1.2.3. By Distribution Channel
15.7.1.2.4. By Service Providers
15.7.2. Italy Market
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast by Market Taxonomy
15.7.2.2.1. By Indication
15.7.2.2.2. By Diagnosis & Treatment Type
15.7.2.2.3. By Distribution Channel
15.7.2.2.4. By Service Providers
15.7.3. France Market
15.7.3.1. Introduction
15.7.3.2. Market Analysis and Forecast by Market Taxonomy
15.7.3.2.1. By Indication
15.7.3.2.2. By Diagnosis & Treatment Type
15.7.3.2.3. By Distribution Channel
15.7.3.2.4. By Service Providers
15.7.4. United Kingdom Market
15.7.4.1. Introduction
15.7.4.2. Market Analysis and Forecast by Market Taxonomy
15.7.4.2.1. By Indication
15.7.4.2.2. By Diagnosis & Treatment Type
15.7.4.2.3. By Distribution Channel
15.7.4.2.4. By Service Providers
15.7.5. Spain Market
15.7.5.1. Introduction
15.7.5.2. Market Analysis and Forecast by Market Taxonomy
15.7.5.2.1. By Indication
15.7.5.2.2. By Diagnosis & Treatment Type
15.7.5.2.3. By Distribution Channel
15.7.5.2.4. By Service Providers
15.7.6. BENELUX Market
15.7.6.1. Introduction
15.7.6.2. Market Analysis and Forecast by Market Taxonomy
15.7.6.2.1. By Indication
15.7.6.2.2. By Diagnosis & Treatment Type
15.7.6.2.3. By Distribution Channel
15.7.6.2.4. By Service Providers
15.7.7. Nordic Countries Market
15.7.7.1. Introduction
15.7.7.2. Market Analysis and Forecast by Market Taxonomy
15.7.7.2.1. By Indication
15.7.7.2.2. By Diagnosis & Treatment Type
15.7.7.2.3. By Distribution Channel
15.7.7.2.4. By Service Providers
15.7.8. Russia Market
15.7.8.1. Introduction
15.7.8.2. Market Analysis and Forecast by Market Taxonomy
15.7.8.2.1. By Indication
15.7.8.2.2. By Diagnosis & Treatment Type
15.7.8.2.3. By Distribution Channel
15.7.8.2.4. By Service Providers
16. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million)Trend Analysis By Market Taxonomy, 2012 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Thailand
16.3.1.3. Indonesia
16.3.1.4. Malaysia
16.3.1.5. Philippines
16.3.1.6. Vietnam
16.3.1.7. Rest of South Asia
16.3.2. By Indication
16.3.3. By Diagnosis & Treatment Type
16.3.4. By Distribution Channel
16.3.5. By Service Providers
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Indication
16.4.3. By Diagnosis & Treatment Type
16.4.4. By Distribution Channel
16.4.5. By Service Providers
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
16.7. Country Level Analysis & Forecast
16.7.1. India Market
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast by Market Taxonomy
16.7.1.2.1. By Indication
16.7.1.2.2. By Diagnosis & Treatment Type
16.7.1.2.3. By Distribution Channel
16.7.1.2.4. By Service Providers
16.7.2. Thailand Market
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast by Market Taxonomy
16.7.2.2.1. By Indication
16.7.2.2.2. By Diagnosis & Treatment Type
16.7.2.2.3. By Distribution Channel
16.7.2.2.4. By Service Providers
16.7.3. Indonesia Market
16.7.3.1. Introduction
16.7.3.2. Market Analysis and Forecast by Market Taxonomy
16.7.3.2.1. By Indication
16.7.3.2.2. By Diagnosis & Treatment Type
16.7.3.2.3. By Distribution Channel
16.7.3.2.4. By Service Providers
16.7.4. Malaysia Market
16.7.4.1. Introduction
16.7.4.2. Market Analysis and Forecast by Market Taxonomy
16.7.4.2.1. By Indication
16.7.4.2.2. By Diagnosis & Treatment Type
16.7.4.2.3. By Distribution Channel
16.7.4.2.4. By Service Providers
16.7.5. Philippines Market
16.7.5.1. Introduction
16.7.5.2. Market Analysis and Forecast by Market Taxonomy
16.7.5.2.1. By Indication
16.7.5.2.2. By Diagnosis & Treatment Type
16.7.5.2.3. By Distribution Channel
16.7.5.2.4. By Service Providers
16.7.6. Vietnam Market
16.7.6.1. Introduction
16.7.6.2. Market Analysis and Forecast by Market Taxonomy
16.7.6.2.1. By Indication
16.7.6.2.2. By Diagnosis & Treatment Type
16.7.6.2.3. By Distribution Channel
16.7.6.2.4. By Service Providers
17. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million)Trend Analysis By Market Taxonomy, 2012 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By Indication
17.3.3. By Diagnosis & Treatment Type
17.3.4. By Distribution Channel
17.3.5. By Service Providers
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Indication
17.4.3. By Diagnosis & Treatment Type
17.4.4. By Distribution Channel
17.4.5. By Service Providers
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis
17.7. Country Level Analysis & Forecast
17.7.1. China Market
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast by Market Taxonomy
17.7.1.2.1. By Indication
17.7.1.2.2. By Diagnosis & Treatment Type
17.7.1.2.3. By Distribution Channel
17.7.1.2.4. By Service Providers
17.7.2. Japan Market
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast by Market Taxonomy
17.7.2.2.1. By Indication
17.7.2.2.2. By Diagnosis & Treatment Type
17.7.2.2.3. By Distribution Channel
17.7.2.2.4. By Service Providers
17.7.3. South Korea Market
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast by Market Taxonomy
17.7.3.2.1. By Indication
17.7.3.2.2. By Diagnosis & Treatment Type
17.7.3.2.3. By Distribution Channel
17.7.3.2.4. By Service Providers
18. Oceania Market Analysis 2012 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Indication
18.3.3. By Diagnosis & Treatment Type
18.3.4. By Distribution Channel
18.3.5. By Service Providers
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Indication
18.4.3. By Diagnosis & Treatment Type
18.4.4. By Distribution Channel
18.4.5. By Service Providers
18.5. Key Market Participants - Intensity Mapping
18.6. Drivers and Restraints - Impact Analysis
18.7. Country Level Analysis & Forecast
18.7.1. Australia Market
18.7.1.1. Introduction
18.7.1.2. Market Analysis and Forecast by Market Taxonomy
18.7.1.2.1. By Indication
18.7.1.2.2. By Diagnosis & Treatment Type
18.7.1.2.3. By Distribution Channel
18.7.1.2.4. By Service Providers
18.7.2. New Zealand Market
18.7.2.1. Introduction
18.7.2.2. Market Analysis and Forecast by Market Taxonomy
18.7.2.2.1. By Indication
18.7.2.2.2. By Diagnosis & Treatment Type
18.7.2.2.3. By Distribution Channel
18.7.2.2.4. By Service Providers
19. Middle East & Africa Market Analysis 2012 to 2022and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2022
19.3. Current and Future Market Size (US$ Million)Analysis and Forecast By Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Türkiye
19.3.1.3. South Africa
19.3.1.4. North Africa
19.3.1.5. Rest of MEA
19.3.2. By Indication
19.3.3. By Diagnosis & Treatment Type
19.3.4. By Distribution Channel
19.3.5. By Service Providers
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Indication
19.4.3. By Diagnosis & Treatment Type
19.4.4. By Distribution Channel
19.4.5. By Service Providers
19.5. Key Market Participants - Intensity Mapping
19.6. Drivers and Restraints - Impact Analysis
19.7. Country Level Analysis & Forecast
19.7.1. GCC Countries Market
19.7.1.1. Introduction
19.7.1.2. Market Analysis and Forecast by Market Taxonomy
19.7.1.2.1. By Indication
19.7.1.2.2. By Diagnosis & Treatment Type
19.7.1.2.3. By Distribution Channel
19.7.1.2.4. By Service Providers
19.7.2. Türkiye Market
19.7.2.1. Introduction
19.7.2.2. Market Analysis and Forecast by Market Taxonomy
19.7.2.2.1. By Indication
19.7.2.2.2. By Diagnosis & Treatment Type
19.7.2.2.3. By Distribution Channel
19.7.2.2.4. By Service Providers
19.7.3. South Africa Market
19.7.3.1. Introduction
19.7.3.2. Market Analysis and Forecast by Market Taxonomy
19.7.3.2.1. By Indication
19.7.3.2.2. By Diagnosis & Treatment Type
19.7.3.2.3. By Distribution Channel
19.7.3.2.4. By Service Providers
19.7.4. North Africa Market
19.7.4.1. Introduction
19.7.4.2. Market Analysis and Forecast by Market Taxonomy
19.7.4.2.1. By Indication
19.7.4.2.2. By Diagnosis & Treatment Type
19.7.4.2.3. By Distribution Channel
19.7.4.2.4. By Service Providers
20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Benchmarking
20.3. Competition Deep Dive
20.3.1. Medtronic Plc
20.3.1.1. Overview
20.3.1.2. Product Portfolio
20.3.1.3. Key Financial
20.3.1.4. Sales Footprint
20.3.1.5. SWOT Analysis
20.3.1.6. Key Developments
20.3.1.7. Strategy Overview
20.3.1.7.1. Marketing Strategies
20.3.1.7.2. Product Strategies
20.3.1.7.3. Channel Strategies
20.3.2. Piramal Enterprises Ltd.
20.3.2.1. Overview
20.3.2.2. Product Portfolio
20.3.2.3. Key Financial
20.3.2.4. Sales Footprint
20.3.2.5. SWOT Analysis
20.3.2.6. Key Developments
20.3.2.7. Strategy Overview
20.3.2.7.1. Marketing Strategies
20.3.2.7.2. Product Strategies
20.3.2.7.3. Channel Strategies
20.3.3. AbbVie, Inc. (Allergan)
20.3.3.1. Overview
20.3.3.2. Product Portfolio
20.3.3.3. Key Financial
20.3.3.4. Sales Footprint
20.3.3.5. SWOT Analysis
20.3.3.6. Key Developments
20.3.3.7. Strategy Overview
20.3.3.7.1. Marketing Strategies
20.3.3.7.2. Product Strategies
20.3.3.7.3. Channel Strategies
20.3.4. Ipsen Pharma
20.3.4.1. Overview
20.3.4.2. Product Portfolio
20.3.4.3. Key Financial
20.3.4.4. Sales Footprint
20.3.4.5. SWOT Analysis
20.3.4.6. Key Developments
20.3.4.7. Strategy Overview
20.3.4.7.1. Marketing Strategies
20.3.4.7.2. Product Strategies
20.3.4.7.3. Channel Strategies
20.3.5. F. Hoffmann-La Roche Ltd
20.3.5.1. Overview
20.3.5.2. Product Portfolio
20.3.5.3. Key Financial
20.3.5.4. Sales Footprint
20.3.5.5. SWOT Analysis
20.3.5.6. Key Developments
20.3.5.7. Strategy Overview
20.3.5.7.1. Marketing Strategies
20.3.5.7.2. Product Strategies
20.3.5.7.3. Channel Strategies
20.3.6. GlaxoSmithKline plc
20.3.6.1. Overview
20.3.6.2. Product Portfolio
20.3.6.3. Key Financial
20.3.6.4. Sales Footprint
20.3.6.5. SWOT Analysis
20.3.6.6. Key Developments
20.3.6.7. Strategy Overview
20.3.6.7.1. Marketing Strategies
20.3.6.7.2. Product Strategies
20.3.6.7.3. Channel Strategies
20.3.7. Pfizer Inc.
20.3.7.1. Overview
20.3.7.2. Product Portfolio
20.3.7.3. Key Financial
20.3.7.4. Sales Footprint
20.3.7.5. SWOT Analysis
20.3.7.6. Key Developments
20.3.7.7. Strategy Overview
20.3.7.7.1. Marketing Strategies
20.3.7.7.2. Product Strategies
20.3.7.7.3. Channel Strategies
20.3.8. Elite Pharmaceuticals Inc.
20.3.8.1. Overview
20.3.8.2. Product Portfolio
20.3.8.3. Key Financial
20.3.8.4. Sales Footprint
20.3.8.5. SWOT Analysis
20.3.8.6. Key Developments
20.3.8.7. Strategy Overview
20.3.8.7.1. Marketing Strategies
20.3.8.7.2. Product Strategies
20.3.8.7.3. Channel Strategies
20.3.9. Orient Pharma
20.3.9.1. Overview
20.3.9.2. Product Portfolio
20.3.9.3. Key Financial
20.3.9.4. Sales Footprint
20.3.9.5. SWOT Analysis
20.3.9.6. Key Developments
20.3.9.7. Strategy Overview
20.3.9.7.1. Marketing Strategies
20.3.9.7.2. Product Strategies
20.3.9.7.3. Channel Strategies
20.3.10. Acorda Therapeutics, Inc.
20.3.10.1. Overview
20.3.10.2. Product Portfolio
20.3.10.3. Key Financial
20.3.10.4. Sales Footprint
20.3.10.5. SWOT Analysis
20.3.10.6. Key Developments
20.3.10.7. Strategy Overview
20.3.10.7.1. Marketing Strategies
20.3.10.7.2. Product Strategies
20.3.10.7.3. Channel Strategies
20.3.11. Sun Pharmaceutical Industries Ltd
20.3.11.1. Overview
20.3.11.2. Product Portfolio
20.3.11.3. Key Financial
20.3.11.4. Sales Footprint
20.3.11.5. SWOT Analysis
20.3.11.6. Key Developments
20.3.11.7. Strategy Overview
20.3.11.7.1. Marketing Strategies
20.3.11.7.2. Product Strategies
20.3.11.7.3. Channel Strategies
20.3.12. Novartis AG (Alcon)
20.3.12.1. Overview
20.3.12.2. Product Portfolio
20.3.12.3. Key Financial
20.3.12.4. Sales Footprint
20.3.12.5. SWOT Analysis
20.3.12.6. Key Developments
20.3.12.7. Strategy Overview
20.3.12.7.1. Marketing Strategies
20.3.12.7.2. Product Strategies
20.3.12.7.3. Channel Strategies
20.3.13. Teva Pharmaceutical Industries Ltd
20.3.13.1. Overview
20.3.13.2. Product Portfolio
20.3.13.3. Key Financial
20.3.13.4. Sales Footprint
20.3.13.5. SWOT Analysis
20.3.13.6. Key Developments
20.3.13.7. Strategy Overview
20.3.13.7.1. Marketing Strategies
20.3.13.7.2. Product Strategies
20.3.13.7.3. Channel Strategies
20.3.14. Zydus Cadila Healthcare Ltd.
20.3.14.1. Overview
20.3.14.2. Product Portfolio
20.3.14.3. Key Financial
20.3.14.4. Sales Footprint
20.3.14.5. SWOT Analysis
20.3.14.6. Key Developments
20.3.14.7. Strategy Overview
20.3.14.7.1. Marketing Strategies
20.3.14.7.2. Product Strategies
20.3.14.7.3. Channel Strategies
20.3.15. Beximco Pharmaceuticals Ltd
20.3.15.1. Overview
20.3.15.2. Product Portfolio
20.3.15.3. Key Financial
20.3.15.4. Sales Footprint
20.3.15.5. SWOT Analysis
20.3.15.6. Key Developments
20.3.15.7. Strategy Overview
20.3.15.7.1. Marketing Strategies
20.3.15.7.2. Product Strategies
20.3.15.7.3. Channel Strategies
20.3.16. Merz Pharma
20.3.16.1. Overview
20.3.16.2. Product Portfolio
20.3.16.3. Key Financial
20.3.16.4. Sales Footprint
20.3.16.5. SWOT Analysis
20.3.16.6. Key Developments
20.3.16.7. Strategy Overview
20.3.16.7.1. Marketing Strategies
20.3.16.7.2. Product Strategies
20.3.16.7.3. Channel Strategies
20.3.17. Thought Technology Ltd.
20.3.17.1. Overview
20.3.17.2. Product Portfolio
20.3.17.3. Key Financial
20.3.17.4. Sales Footprint
20.3.17.5. SWOT Analysis
20.3.17.6. Key Developments
20.3.17.7. Strategy Overview
20.3.17.7.1. Marketing Strategies
20.3.17.7.2. Product Strategies
20.3.17.7.3. Channel Strategies
20.3.18. UltraCare PRO
20.3.18.1. Overview
20.3.18.2. Product Portfolio
20.3.18.3. Key Financial
20.3.18.4. Sales Footprint
20.3.18.5. SWOT Analysis
20.3.18.6. Key Developments
20.3.18.7. Strategy Overview
20.3.18.7.1. Marketing Strategies
20.3.18.7.2. Product Strategies
20.3.18.7.3. Channel Strategies
20.3.19. Invacare Corporation
20.3.19.1. Overview
20.3.19.2. Product Portfolio
20.3.19.3. Key Financial
20.3.19.4. Sales Footprint
20.3.19.5. SWOT Analysis
20.3.19.6. Key Developments
20.3.19.7. Strategy Overview
20.3.19.7.1. Marketing Strategies
20.3.19.7.2. Product Strategies
20.3.19.7.3. Channel Strategies
20.3.20. ATI Physical Therapy
20.3.20.1. Overview
20.3.20.2. Product Portfolio
20.3.20.3. Key Financial
20.3.20.4. Sales Footprint
20.3.20.5. SWOT Analysis
20.3.20.6. Key Developments
20.3.20.7. Strategy Overview
20.3.20.7.1. Marketing Strategies
20.3.20.7.2. Product Strategies
20.3.20.7.3. Channel Strategies
20.3.21. P.T. Services Rehabilitation, Inc.
20.3.21.1. Overview
20.3.21.2. Product Portfolio
20.3.21.3. Key Financial
20.3.21.4. Sales Footprint
20.3.21.5. SWOT Analysis
20.3.21.6. Key Developments
20.3.21.7. Strategy Overview
20.3.21.7.1. Marketing Strategies
20.3.21.7.2. Product Strategies
20.3.21.7.3. Channel Strategies
20.3.22. Banner Health
20.3.22.1. Overview
20.3.22.2. Product Portfolio
20.3.22.3. Key Financial
20.3.22.4. Sales Footprint
20.3.22.5. SWOT Analysis
20.3.22.6. Key Developments
20.3.22.7. Strategy Overview
20.3.22.7.1. Marketing Strategies
20.3.22.7.2. Product Strategies
20.3.22.7.3. Channel Strategies
21. Assumptions and Acronyms Used
22. Research Methodology
Explore Healthcare Insights
View Reports
Spasticity Treatment Market
